What ALS Is and How It Progresses
ALS, or amyotrophic lateral sclerosis, is a progressive neurodegenerative disease that affects motor neurons in the brain and spinal cord. As these neurons deteriorate, muscles weaken, leading to increasing disability and, eventually, respiratory failure. According to the ALS Association, average survival after diagnosis is two to five years, though some patients live longer with supportive care and newer therapies. The rate of progression varies widely between individuals, influenced by genetics, age, and site of onset.
Early symptoms often include muscle twitching, cramping, stiffness, and difficulty speaking or swallowing. As the disease advances, patients lose the ability to walk, use their hands, and breathe independently. Because ALS impacts each person differently, clinicians use scales such as the ALSFRS-R to track functional decline and estimate how quickly the disease is worsening. Understanding this trajectory is essential for evaluating whether a treatment can meaningfully slow ALS.
Can ALS Be Slowed Down With Current Treatments?
Several therapies have been approved by the FDA that modestly slow ALS progression. Riluzole, approved in 1995, extends survival by roughly two to three months on average by reducing glutamate excitotoxicity. Edaravone, approved in 2017, slows the decline in physical function in select patients, particularly those with early-stage disease. More recently, the FDA approved tofersen for SOD1-ALS, a genetic subtype, with clinical data showing reductions in neurofilament light chain and slowed functional decline.
Combination therapy and multidisciplinary care, including noninvasive ventilation and nutritional support, also contribute to longer survival. A study cited by the ALS Therapy Development Institute found that patients receiving comprehensive care in certified centers experienced slower functional decline compared to those without structured support. These outcomes underscore that while ALS cannot yet be stopped, a combination of approved drugs and proactive care can slow ALS in many patients.
Emerging Therapies and Clinical Trials Targeting ALS Progression
Researchers are testing dozens of experimental drugs aimed at slowing ALS through different mechanisms, including neuroinflammation, protein aggregation, and gene therapy. Companies like Biogen, Ionis Pharmaceuticals, and Wave Life Sciences are advancing antisense oligonucleotides and RNA-targeted therapies for genetic forms of ALS. Clinical trials registered on ClinicalTrials.gov continue to expand, with several phase 3 studies evaluating whether newer compounds can slow ALS more effectively than existing options.
Patient advocacy groups and organizations such as the ALS Association and Muscular Dystrophy Association fund and facilitate trials, helping accelerate the path from lab to clinic. For those interested in the latest research and trial opportunities, the ALS Therapy Development Institute provides up-to-date information on experimental treatments and how they aim to slow ALS. Patients and caregivers can also explore trial participation through resources maintained by the National Institute of Neurological Disorders and Stroke.